Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on AnaptysBio Inc (NASDAQ:ANAB) and Alder Biopharmaceuticals (NASDAQ:ALDR).
AnaptysBio Inc (ANAB)
In a report released yesterday, Kennen MacKay from RBC Capital reiterated a Hold rating on AnaptysBio Inc, with a price target of $84. The company’s shares opened today at $81.64.
According to TipRanks.com, MacKay is a 5-star analyst with an average return of 19.5% and a 61.5% success rate. MacKay covers the Healthcare sector, focusing on stocks such as Spark Therapeutics, Seattle Genetics, and Acceleron Pharma.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for AnaptysBio Inc with a $125 average price target.
See today’s analyst top recommended stocks >>
Alder Biopharmaceuticals (ALDR)
In a report released yesterday, Brian Abrahams from RBC Capital reiterated a Buy rating on Alder Biopharmaceuticals, with a price target of $27. The company’s shares opened today at $19.85, close to its 52-week high of $20.87.
According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 12.5% and a 55.9% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, Intra-Cellular Therapies, and Karyopharm Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alder Biopharmaceuticals with a $25.67 average price target, implying a 29.3% upside from current levels. In a report issued on August 6, Piper Jaffray also initiated coverage with a Buy rating on the stock with a $28 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
